Anti-Fibrinolytic Drugs - Mozambique

Mozambique

In Mozambique, the revenue in the market of Anti-Fibrinolytic Drugs market is estimated to reach US$2.25m by the year 2024.
It is expected that the revenue will exhibit a compound annual growth rate (CAGR 2024-2029) of 6.82%, leading to a market volume of US$3.13m by 2029.
When compared globally, United States is projected to generate the highest revenue of US$9,858.00m in 2024.
Mozambique is witnessing a growing demand for anti-fibrinolytic drugs due to an increasing prevalence of cardiovascular diseases in the country.

Key regions: United Kingdom, Brazil, Europe, France, Canada

Market

Region

Region comparison

Currency

Analyst Opinion

The Anti-Fibrinolytic Drugs market in Mozambique is experiencing significant growth due to several factors.

Customer preferences: Mozambique has a high prevalence of bleeding disorders, which has led to an increase in demand for Anti-Fibrinolytic Drugs. Additionally, the country has a large population of women who are prone to postpartum hemorrhage, making Anti-Fibrinolytic Drugs a popular choice in the obstetrics and gynecology field.

Trends in the market: The Anti-Fibrinolytic Drugs market in Mozambique is expected to grow due to the increasing incidence of bleeding disorders, which is linked to the high prevalence of HIV/AIDS in the country. The government's efforts to improve healthcare services and increase access to medication are also contributing to the growth of the market.

Local special circumstances: Mozambique has a limited healthcare infrastructure, which can make it difficult for patients to access medication. As a result, many patients opt for traditional medicine or seek treatment from traditional healers. However, the government has recognized the importance of improving healthcare services and is working to increase access to medication.

Underlying macroeconomic factors: Mozambique is one of the poorest countries in the world, with a low per capita income and high levels of poverty. This can make it challenging for patients to afford medication, particularly those with chronic conditions. However, the government has implemented policies to improve access to healthcare services, including the provision of free medication to certain groups of patients. Additionally, the country has experienced economic growth in recent years, which has led to an increase in healthcare spending.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.